Gallium 67 citrate scanning in neoplastic and inflammatory lesions

Lavender, J. P.; Lowe, June; Barker, Jared; Burn, J. H.; Chaudhri, M. Anwar

doi:10.1259/0007-1285-44-521-361

Cited by 296 publications

(62 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hence, uptake is nonspecific; for example, Lavender et al (1971) detected concentration in an inflammatory lesion, and in our own series two patients with penumonia had positive scans.…”

Section: Discussionmentioning

confidence: 58%

Use of gallium‐67 scanning in the management of lymphoma

Bakshi

Bender

1973

Journal of Surgical Oncology

View full text Add to dashboard Cite

There has been considerable interest recently in the possibility that gallium‐67 citrate may be of clinical value as a tumor seeking scanning agent. Since its discovery by Edwards and Hayes (1969), a number of reports have been published recording uptake in a variety of tumors, both primary and metastatic (Higasi et al., 1970; Winchell et al., 1970). The observation of Hayes et al. (1970), based on autoradiographs of experimental tumors, that the radioisotope is taken up in the cytoplasm in malignant cells and that uptake is greater in viable than in necrotic tumor has stimulated its use in following patients with lymphoma to assess the efficacy of the therapy administeted. At our Institution an assessment has been made of the potential value of 67Ga citrate scanning in the management of lymphoma. Interesting scans showing the usefulness and difficulties with this agent are presented. A total of 79 scans were reviewed. The majority of the patients studied has received either chemotherapy or radiotherapy prior to scanning. Uptake was detected in 42 cases with active disease (53%); no uptake was noted in 28 cases (36%) without active disease, and in 9 cases (11%) the scan gave a false‐positive or a false‐negative result. The conclusions of this study are (1) 67Ga scanning is useful in establishing the extent of lesions as well as the presence of undetected disease, (2) 67Ga scanning is especially useful for the evaluation of the effectiveness of therapy.

show abstract

“…Hence, uptake is nonspecific; for example, Lavender et al (1971) detected concentration in an inflammatory lesion, and in our own series two patients with penumonia had positive scans.…”

Section: Discussionmentioning

confidence: 58%

Use of gallium‐67 scanning in the management of lymphoma

Bakshi

Bender

1973

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…These studies suggest that the radiolabelled IL-2 could be used as a potential radiopharmaceutical for scintigraphic imaging of chronic inflammation. 67 Ga-citrate as a radiopharmaceutical for imaging infection and inflammation was discovered in 1971 (Lavender et al, 1971). As an analogue of iron, 67 Ga-citrate binds in ionic form to circulating transferrin.…”

Section: Interleukinmentioning

confidence: 99%

Radiopharmaceuticals for imaging chronic lymphocytic inflammation

Malviya

Vries

Dierckx

et al. 2007

Braz. arch. biol. technol.

View full text Add to dashboard Cite

In the last few decades, a number of radiopharmaceuticals for imaging inflammation have been proposed that differ in their specificity and mechanism of uptake in inflamed foci as compared to the traditional inflammation imaging agents. Radiolabelled cytokines represent a reliable tool for the preclinical diagnosis of chronic inflammatory processes, even before anatomical and functional changes occur in affected tissues. Moreover, the introduction of radiolabelled monoclonal antibodies and sophisticated technique like PET/CT now make the field of inflammationimaging highly specific and accurate. In this review, different approaches of the established and experimental radiopharmaceuticals for imaging of chronic inflammation are discussed.

show abstract

“…In 1969, Edwards and Hayes noted the potential use of gallium 67 (67Ga) citrate as a tumor scanning agent for Hodgkin's Offprint requests to: J. L. Domingo disease. Since then, 67Ga has been shown to localize in a variety of tumors as well as in inflammatory lesions (Lavender et al 1971;Ando etal. 1990).…”

Section: Introductionmentioning

confidence: 99%

Developmental toxicity evaluation of gallium nitrate in mice

et al. 1992

View full text Add to dashboard Cite

Gallium nitrate, a drug with antitumor activity, is presently undergoing clinical trials as a chemotherapeutic agent for the treatment of certain malignancies. Since there are very limited published animal toxicity data available, this study was conducted to investigate the potential adverse developmental effects of this drug. Pregnant Swiss mice were administered intraperitoneally gallium nitrate at 12.5, 25, 50, and 100 mg/kg/day on days 6, 8, 10, 12, and 14 of gestation. Monitors for maternal toxicity were body weight, food consumption and clinical signs. At sacrifice (day 18) maternal weight, liver and kidney weights, and gravid uterine weights were measured. Gestational parameters monitored were numbers of total implants, resorptions, postimplantation losses, and dead fetuses. Live fetuses were sexed, weighted, and examined for external, internal and skeletal malformations and variations. Maternal toxicity was noted in all the gallium nitrate-treated groups. Embryo/fetal toxicity was evidenced by a decrease in the number of viable implants, a reduction in fetal weight, and an increase in the number of skeletal variations (12.5, 25, 50 and 100 mg/kg). No significant increase in the incidence of malformations was observed at 12.5, 25, or 50 mg/kg. The no-observable-adverse-effect level (NOAEL) for both maternal and developmental toxicity of gallium nitrate was less than 12.5 mg/kg.

show abstract

Gallium 67 citrate scanning in neoplastic and inflammatory lesions

Cited by 296 publications

References 6 publications

Use of gallium‐67 scanning in the management of lymphoma

Use of gallium‐67 scanning in the management of lymphoma

Radiopharmaceuticals for imaging chronic lymphocytic inflammation

Developmental toxicity evaluation of gallium nitrate in mice

Contact Info

Product

Resources

About